Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 3/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.33 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31720361 | 0.92 | GLP1R (0.44) | GLP1RAKT1PLK1PSEN1PSEN2 | |
| SCHEMBL29467713 | 0.91 | GLP1R (0.44) | GLP1RAKT1PLK1PSEN1PSEN2 | |
| SCHEMBL23451364 | 0.91 | GLP1R (0.44) | GLP1RAKT1PLK1PSEN1PSEN2 | |
| SCHEMBL23451366 | 0.91 | GLP1R (0.44) | GLP1RAKT1PLK1PSEN1PSEN2 | |
| SCHEMBL30407076 | 0.91 | GLP1R (0.46) | GLP1R | |
| SCHEMBL30407467 | 0.89 | GLP1R (0.40) | GLP1RAKT1PSMB1PSMB5PSMB2 | |
| SCHEMBL30407107 | 0.87 | GLP1R (0.39) | GLP1RAKT1PSMB1PSMB5PSMB2 | |
| SCHEMBL25332401 | 0.87 | GLP1R (0.41) | GLP1RAKT1PLK1PSEN1PSEN2 | |
| SCHEMBL29467572 | 0.87 | GLP1R (0.41) | GLP1RAKT1PLK1PSEN1PSEN2 | |
| SCHEMBL30408925 | 0.86 | GLP1R (0.42) | GLP1RAKT1PLK1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | GLP1R 2116/4885AKT1 2347/4885PLK1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.